A Study of IPL344 in the Treatment of ALS Patients

Summary

This is a prospective, open-label, phase 1/2a study, dose escalation, to evaluate tolerability, safety, and PK of I.V. administered IPL344 in participants with Amyotrophic Lateral Sclerosis (ALS).

Timeline

Start

2018-08-01

Primary completion

2026-01

Completion

2026-02

Outcome

Outcome not reported

Stopped: “Study was suspended due to IPL344 shortage and may resume once drug supply is available.”

Drugs

Indications